Skip to content

Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients – The Wall Street Journal

Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients  The Wall Street JournalMedicare will cover Biogen’s $28K Alzheimer’s drug, only in trials  CNBC TelevisionMedicare Part B Premium Hike Could Be Reduced as Government Reassesses Alzheimer’s Drug  GOBankingRatesBiogen’s Alzheimer’s Drug Coverage Limited by U.S.  Bloomberg Markets and FinanceMedicare Proposes to Sharply Limit Coverage of the Alzheimer’s Drug Aduhelm  The New York TimesView Full Coverage on Google News

Leave a Reply

Your email address will not be published. Required fields are marked *